Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30357916 | 0.98 | SLC6A4 (0.96) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL5218770 | 0.98 | SLC6A4 (0.96) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL6219350 | 0.86 | SLC6A2 (0.75) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL10605496 | 0.84 | SLC6A2 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23897956 | 0.84 | SLC6A2 (0.72) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14956384 | 0.84 | SLC6A2 (0.72) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL14311996 | 0.84 | SLC6A2 (0.72) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL942585 | 0.81 | SLC6A2 (0.69) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31128128 | 0.81 | SLC6A2 (0.69) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31532489 | 0.81 | SLC6A2 (0.68) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | claimed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | claimed |
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| CN-109963834-B | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2023-04-14 | — | — | CN | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| EP-3541784-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| CN-109963834-A | It can be used as the novel azetidine derivatives of cortex catecholaminergic modulators of neurotransmission | 综合研究实验室瑞典股份公司 | 2019-07-02 | — | — | CN | disclosed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113297-A9 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 5/4885SLC6A2 2/4885SLC6A3 4/4885 |
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | SLC6A4 1827/4885SLC6A2 3167/4885SLC6A3 2165/4885 |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | SLC18A1, CHRM1, CHRM2 | SLC6A4 64/4885SLC6A2 21/4885SLC6A3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.